Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

Sakurai, Masatoshi; Kikuchi, Taku; Karigane, Daiki; Kasahara, Hidenori; Matsuki, Eri; Hashida, Risa; Yamane, Yusuke; Abe, Ryohei; Koda, Yuya; Toyama, Toshio; Kato, Jun; Shioiri, Takayuki; Yokoyama, Yuta; Suzuki, Sayo; Nakamura, Tomonori; Okamoto, Shinichiro; Mori, Takehiko

doi:10.1007/s12185-019-02596-z

Cited by 17 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imatinib therapy can rarely be associated with potentially irreversible acute renal injury (62). Imatinib long-term treatment may cause a clinically relevant decrease in the estimated glomerular filtration rate and hemoglobin levels that can improve after treatment discontinuation (63). No serious long-term exposure toxicity has been related to imatinib (1).…”

Section: Safety Considerationsmentioning

confidence: 99%

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

2019

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near normal life-expectancy. However, since the majority of patients will need to remain on treatment indefinitely, physicians in care of CML patients need be familiar with the indications and toxicities of all approved tyrosine kinase inhibitors (TKI). In clinical practice, there are five TKI (imatinib, nilotinib, dasatinib, bosutinib, and ponatinib) that are available in different scenarios and have distinct safety profiles. Decisions regarding first line treatment must be based on CML risk, comorbidities, and patients expectations. Despite the excellent outcome, half of the patients will eventually fail (due to intolerance or resistance) to first line treatment, with many of them requiring a third or even further lines of therapy. When selecting for such patients, it is essential to distinguish between failure and intolerance to previous TKIs. In the present review, we will address all these issues from a practical point of view.

show abstract

Section: Safety Considerationsmentioning

confidence: 99%

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

2019

View full text Add to dashboard Cite

show abstract

“…All included studies [10][11][12]16,18,[20][21][22] were retrospective cohort in nature except the study by Marcolino et al, 17 which was prospective in nature.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Studies were conducted between 2011 and 2020. Three studies were conducted in Japan, 10,21,22 two in the US, 11,12 one in each Brazil, 17 China, 20 and Italy. 18 The current study was based on 1680 patients exposed to imatinib, and the mean follow-up period of the patients was 6.64 years.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…At the baseline, patients in all the included studies were in stage-II CKD (eGFR between 60 and 89 ml/min/1.73 m 2 ) except in the study by Cortes et al (stage-III CKD). 16 Four studies used diet modification in the renal disease method, 12,16,20,21 while two studies used Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI) 17,18 to compute the eGFR. Diabetes mellitus and hypertension were the most common co-morbidities reported in the included studies (n = 7).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…10,21 Yilmaz et al12 examined the impact of imatinib, nilotinib, and dasatinib on renal dysfunction and concluded that only imatinib impaired renal function, not the nilotinib or dasatinib. A similar finding was reported byMolica et al …”

mentioning

confidence: 99%

See 2 more Smart Citations

Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients

et al. 2022

View full text Add to dashboard Cite

Background: Recently, multiple epidemiological studies have linked imatinib with the alteration of renal function in chronic myeloid leukaemia (CML) patients. This metaanalysis aimed to summarize the impact of imatinib use on renal function in CML patients.Methods: A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients.

show abstract

Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa

Ayalew,

Azibte,

Tadesse

et al. 2024

eJHaem

View full text Add to dashboard Cite

IntroductionThe efficacy of BCR‐ABL tyrosine kinase inhibitors (TKIs) in treating chronic myelogenous leukemia and other malignancies is well‐documented. However, concerns about potential nephrotoxicity have raised questions. This study, conducted at Tikur Anbesa Specialized Hospital (TASH) in Addis Ababa, Ethiopia, aimed to investigate the association between TKIs and renal toxicities.MethodsA hospital‐based cross‐sectional design was used to enroll 260 TASH patients actively receiving BCR‐ABL TKIs. Demographic information, diagnoses, treatment details, and laboratory test results were collected for each participant's Electronic Medical Record. The primary goal was to assess adverse renal events, a combination of events of a decrease in estimated glomerular filtration rate (eGFR) exceeding 30% from baseline, significant proteinuria, and a diagnosis of acute kidney injury (AKI) or chronic kidney disease (CKD). A logistic regression model was used to analyze the data and identify factors associated with developing adverse renal events.ResultsOur analysis revealed a statistically significant decrease in eGFR following treatment with TKIs. However, the observed rate of adverse renal events (13.1%) was lower than reported in some previous studies. Factors significantly associated with adverse renal events included longer TKI duration, male sex (protective), hypertension, HIV infection, and achieving complete molecular remission and/or a complete hematologic response. No significant associations were found with diabetes mellitus, age, angiotensin‐converting enzyme inhibitors use, or baseline creatinine level.ConclusionsWhile this study found that BCR‐ABL TKIs can lead to a decline in eGFR, AKI, and CKD, it also demonstrated that they were relatively safer in our study population.

show abstract

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

Cited by 17 publications

References 31 publications

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients

Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa

Contact Info

Product

Resources

About